top of page
Search
Compass Pathways Brings Psilocybin Therapy for Mental Health Closer to Market
Too long to read? Go for the highlights below. Compass Pathways accelerates its planned commercial launch of COMP360 for treatment-resistant depression by up to a year after favourable engagement with the FDA. Phase 3 data remain the decisive hurdle, with key 9-week and 26-week readouts expected in early 2026. Despite rising losses linked to warrant liability adjustments, the company reports a strengthened cash position sufficient to operate into 2027. Regulatory momentum and
2 days ago
Germany’s Pioneering Psilocybin Program: A New Hope for Depression Treatment
Germany has launched the EU’s first regulated psilocybin program , offering hope for those with severe depression but facing hurdles in...
Aug 28
Oregon’s Psilocybin Program: First Data Reveals Trends and Challenges
The nation’s first regulated psilocybin market shows promise but faces hurdles in accessibility and cost. In 2020, Oregon became the...
Jul 17
Compass Pathways Hits Milestone in Psychedelic Drug Development with Phase 3 Psilocybin Readout for 250+ Patients
Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...
Jun 23
Psilocybin for Depression: A Closer Look at the Evidence
With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...
May 19
bottom of page